Where does Leo Pharma A/S rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Leo Pharma A/S ranks #7,433 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Leo Pharma A/S hold?

Leo Pharma A/S holds 44 US utility patents granted between 2015 and 2025, spanning 10 technology areas.

What is Leo Pharma A/S's Innovation Score?

Leo Pharma A/S has an Innovation Score of 38.8 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Leo Pharma A/S focus on?

Leo Pharma A/S's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 38 patents, ranking #491 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Leo Pharma A/S's patent grant rate increasing or decreasing?

Leo Pharma A/S's recent grant velocity is -35% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Leo Pharma A/S's patents?

Leo Pharma A/S's patents average 20.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Leo Pharma A/S patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Leo Pharma A/S

USPTO PatentsView assignee record - 44 granted patents across 10 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Leo ranks #7,433 of 49,997 tracked US assignees by granted-patent volume, with 44 patents across 10 technology areas.

#7,433
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.8/100): 20.9
avg claims per patent: -35%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7433 · Foreign Corporation #7,433 · 44 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 44 grants
UPPER-Q #7,433/49,997
PHOTO-FINISH Kulzer
CPC-FOCUS A61P · 10 areas
INNOV-THIN 38.8/100
CLAIMS-DENSE 20.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -35% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kulzer GMBH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Leo’s 38.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (34%) Velocity 1.9 pts (5%) Breadth 11.2 pts (29%) Claim depth 12.5 pts (32%)

Qualcomm Incorporated · highest

85
Advanced Architectur… · near

39
Guangdong Jiamei… · near

39
Leo Pharma A/S · this assignee

39
Ligand Pharmaceutica… · near

39
Venatorx Pharmaceuti… · near

39
3D Lighting… · lowest

7

What this shows Leo's Innovation Score is 38.8/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Leo?

Each dot is one of Leo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Leo’s own 20.9 claims/patent is ABOVE the 17.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Leo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Leo's grants concentrate

Leo Pharma A/S is a focused PatentsView assignee: 10 CPC subclasses with 86.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (12 grants) versus a trough of 1 in 2019. By volume, Leo sits between Kulzer GMBH and MIE University.

Leo's three-year grant acceleration

Leo Pharma A/S shows 4 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kulzer

44
Labcyte

44
Lancium

44
LT Materials

44
Lucomm

44
Lunatech

44
Mega Brands

44
MIE University

44
Leo Pharma A/S ◀

44

What this shows Leo holds 44 patents at rank #7,434, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Leo

By rank, the assignees closest to #7,434 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Leo's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Leo, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Leo ranks #491 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (39 here).

Advanced Architectural Products, LLC 39 Venatorx Pharmaceuticals, Inc. 39 Ligand Pharmaceuticals Incorporated 39 Guangdong Jiamei Ceramics Co., Ltd. 39

Leo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Leo Pharma A/S patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	12	27.3%
2016	7	15.9%
2017	3	6.8%
2018	3	6.8%
2019	1	2.3%
2020	10	22.7%
2021	3	6.8%
2022	1	2.3%
2023	1	2.3%
2024	2	4.5%
2025partial year	1	2.3%

Which technologies does Leo Pharma A/S patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 38

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 28

C07D - Heterocyclic Compounds 26

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 8

C07C - Acyclic OR Carbocyclic Compounds 6

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07K - Peptides 2

C07J - Steroids 1

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Leo Pharma A/S's patent record in context - here's where to go next.

Leo Pharma A/S's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 86.4% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #7,433 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Leo Pharma A/S against Kulzer GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.